Abstract
The purpose of the study was to evaluate the effectiveness of caspofungin and voriconazole in the treatment of experimental Aspergillus otits media in an experimental rabbit model. A total of 30 New Zealand white rabbits were divided into four treatment groups and one control group. The rabbits were immunosuppressed by cyclophosphamide and triamcinolone acetonide. The right ear of each rabbit was infected by an injection of the inoculum of 0.1 ml (8.6 × 103 CFU/0.1 ml) of Aspergillus fumigatus into the middle ear cavity. At 72 h after the inoculation, amphotericin B 1 mg/kg per day (n = 6), itraconazole 10 mg/kg per day (n = 6), voriconazole 10 mg/kg per day (n = 6) and caspofungin 5 mg/kg per day (n = 6) were injected to each treatment group. No antifungal drug was administered to the control group (n = 6). Clinical and histopathological examination scores and microbiological analysis of middle ear mucosa were compared.There was statistically significant difference in the clinical scores, histopathological scores, and mean CFU/g between the treatment and control groups (P < 0.05). There was no statistically significant difference among the treatment groups in the clinical and histopathological scores, whereas there was statistically significant difference in the mean CFU/g (P < 0.05). The mean CFU/g of amphotericin B and caspofungin groups were similar and both were lower than the itraconazole and voriconazole groups. Also, the mean CFU/g of voriconazole group was lower than the itraconazole group (P < 0.05). Caspofungin and voriconazole were demonstrated at least as effective as amphotericin B and itraconazole. We suggest that caspofungin and voriconazole may be considered for the treatment of fungal infection of the ear.
Similar content being viewed by others
References
Ohki M, Ito K, Ishimoto S (2001) Fungal mastoiditis in an immunocompetent adult. Eur Arch Otorhinolaryngol 258:106–108
Gussen R, Canalis RF (1982) Mucormycosis of the temporal bone. Ann Otol Rhinol Laryngol 91:27–32
Blackledge FA, Newlands SD (2001) Blastomycosis of the petrous apex. Otolaryngol Head Neck Surg 124:347–349
Bhally HS, Shields C, Lin SY, Merz WG (2004) Otitis caused by Scedosporium apiospermum in an immunocompetent child. Int J Pediatr Otorhinolaryngol 68:975–978
Chang CY, Schell WA, Perfect JR, Hulka GF (2005) Novel use of a swimming pool biocide in the treatment of a rare fungal mastoiditis. Laryngoscope 115:1065–1069
Maschmeyer G, Ruhnke M (2004) Update on antifungal treatment of invasive Candida and Aspergillus infections. Mycoses 47:263–276
Slack CL, Watson DW, Abzug MJ, Shaw C, Chan KH (1999) Fungal mastoiditis in immunocompromised children. Arch Otolaryngol Head Neck Surg 125:73–75
Patterson TF (2005) Advances and challenges in management of invasive mycoses. Lancet 366:1013–1025
Shao PL, Huang LM, Hsueh PR (2007) Recent advances and challenges in the treatment of invasive fungal infections. Int J Antimicrob Agents 30:487–495
Patterson TF, Miniter P, Ryan JL, Andriole VT (1988) Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model. J Infect Dis 158:415–422
Kirkpatrick WR, McAtee RK, Fothergill AW, Loebenberg D, Rinaldi MG, Patterson TF (2000) Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 44:780–782
Sandhu P, Xu X, Bondiskey PJ et al (2004) Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother 48:1272–1280
Kirkpatrick WR, Vallor AC, McAtee RK et al (2005) Combination therapy with terbinafine and amphotericin B in a rabbit model ofexperimental invasive aspergillosis. Antimicrob Agents Chemother 49:4751–4753
Roffey SJ, Cole S, Comby P et al (2003) The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731–741
Lewis RE, Prince RA, Chi J, Kontoyiannis DP (2002) Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 46:3208–3214
Barry B, Muffat-Joly M, Bauchet J et al (1996) Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 40:1977–1982
National Committee for Clinical Laboratory Standards: reference method for broth dilution antifungal susceptibility testing of yeasts (2002) Approved standard, 2nd edn. NCCLS document M27-A2. Wayne, PA: UCCLS
Chirch L, Roche P, Fuhrer J (2008) Successful treatment of invasive Aspergillus sinusitis with caspofungin and voriconazole. Ear Nose Throat J 87:30–33
Amonoo-Kuofi K, Tostevin P, Knight JR (2005) Aspergillus mastoiditis in a patient with systemic lupus erythematosus: a case report. Skull Base 15:109–112
Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new “gold standard”. Clin Infect Dis 37:415–425
Kartsonis NA, Nielsen J, Douglas CM (2003) Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat 6:197–218
Maertens J, Raad I, Petrikkos G et al (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563–1571
Walsh TJ, Teppler H, Donowitz GR et al (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391–1402
Heinz WJ, Einsele H (2008) Caspofungin for treatment of invasive aspergillus infections. Mycoses 51:47–57
Boogaerts M, Winston DJ, Bow EJ et al (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 135:412–422
Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA (2003) Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41:3623–3626
Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415
Denning DW, Ribaud P, Milpied N et al (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571
Troke PF, Schwartz S, Ruhnke M et al. (2003) Voriconazole therapy in 86 patients with CNS aspergillosis: a retrospective analysis. Abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 14–17, M-1755, p 476
Serrano Mdel C, Valverde-Conde A, Chávez MM et al (2003) In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis 45:131–135
Conflict of interest statement
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ayçiçek, A., Çetinkaya, Z., Kiyici, H. et al. The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus . Eur Arch Otorhinolaryngol 266, 1703–1709 (2009). https://doi.org/10.1007/s00405-009-0963-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-009-0963-2